CoChat

Quantitative Targeted Absolute Proteomic Analysis of Transporters, Receptors and Junction Proteins for Validation of Human Cerebral Microvascular Endothelial Cell Line hCMEC/D3 as a Human Blood–Brain Barrier Model

Ohtsuki, Sumio, Ikeda, Chiemi, Uchida, Yasuo, Sakamoto, Yumi, Miller, Florence, Glacial, Fabienne, Decleves, Xavier, Scherrmann, Jean-Michel, Couraud, Pierre-Olivier, Kubo, Yoshiyuki, Tachikawa, Masanori, Terasaki, Tetsuya · 2013 · Molecular Pharmaceutics
Cited by 230

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Human cerebral microvascular endothelial cell line hCMEC/D3 is an established model of the human blood-brain barrier (BBB). The purpose of the present study was to determine, by means of quantitative targeted absolute proteomics, the protein expression levels in hCMEC/D3 cells of multiple transporters, receptors and junction proteins for comparison with our previously reported findings in isolated human brain microvessels. Among 91 target molecules, 12 transporters, 2 receptors, 1 junction protein and 1 membrane marker were present at quantifiable levels in plasma membrane fraction of hCMEC/D3 cells. ABCA2, MDR1, MRP4, BCRP, GLUT1, 4F2hc, MCT1, ENT1, transferrin and insulin receptors and claudin-5 were detected in both hCMEC/D3 cells and human brain microvessels. After normalization based on Na(+)/K(+) ATPase expression, the differences in protein expression levels between hCMEC/D3 cells and human brain microvessels were within 4-fold for these proteins, with the exceptions of ENT1, transferrin receptor and claudin-5. ABCA8, LAT1, LRP1 and γ-GTP were below the limit of quantification in the cells, but were found in human brain microvessels. ABCA3, ABCA6, MRP1 and ATA1 were found only in hCMEC/D3 cells. Furthermore, compared with human umbilical vein endothelial cells (HUVECs) as reference nonbrain endothelial cells, MDR1 was found only in hCMEC/D3 cells, and GLUT1 expression was 15-fold higher in hCMEC/D3 cells than in HUVECs. In conclusion, this is the first study to examine the suitability and limitations of the hCMEC/D3 cell line as a BBB functional model in terms of quantitative expression levels of transporters, receptors and tight junction proteins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/mp3004308

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 35

  1. Ohtsuki S., 2007, Pharm. Res., 24, 1745, 10.1007/s11095-007-9374-5 · DOI · Paper page
  2. Kusuhara H., 2005, NeuroRx, 2, 73, 10.1602/neurorx.2.1.73 · DOI · Paper page
  3. Ohtsuki S., 2007, Pharm. Res., 24, 688, 10.1007/s11095-006-9188-x · DOI
  4. Leino R. L., 1999, Brain Res. Dev. Brain Res., 113, 47, 10.1016/S0165-3806(98)00188-6 · DOI · Paper page
  5. Ohtsuki S., 2006, Biol. Pharm. Bull., 29, 1587, 10.1248/bpb.29.1587 · DOI
  6. Ohtsuki S., 2010, Biol. Pharm. Bull., 33, 1250, 10.1248/bpb.33.1250 · DOI
  7. Che C., 2010, J. Med. Chem., 53, 2814, 10.1021/jm9016637 · DOI · Paper page
  8. Pardridge W. M., 2005, NeuroRx, 2, 129, 10.1602/neurorx.2.1.129 · DOI
  9. Ito S., 2011, J. Cereb. Blood Flow Metab., 31, 457, 10.1038/jcbfm.2010.108 · DOI
  10. Warren M. S., 2009, Pharmacol. Res., 59, 404, 10.1016/j.phrs.2009.02.007 · DOI · Paper page
  11. Ohtsuki S., 2011, J. Pharm. Sci., 100, 3547, 10.1002/jps.22612 · DOI
  12. Uchida Y., 2011, J. Neurochem., 117, 333, 10.1111/j.1471-4159.2011.07208.x · DOI · Paper page
  13. Carl S. M., 2010, Mol. Pharmaceutics, 7, 1057, 10.1021/mp900178j · DOI · Paper page
  14. Dauchy S., 2009, Biochem. Pharmacol., 77, 897, 10.1016/j.bcp.2008.11.001 · DOI · Paper page
  15. Poller B., 2008, J. Neurochem., 107, 1358, 10.1111/j.1471-4159.2008.05730.x · DOI · Paper page
  16. Weksler B. B., 2005, FASEB J., 19, 1872, 10.1096/fj.04-3458fje · DOI · Paper page
  17. Fasler-Kan E., 2010, Brain Res., 1354, 15, 10.1016/j.brainres.2010.07.077 · DOI
  18. Hurst L. A., 2009, J. Neuroimmunol., 210, 108, 10.1016/j.jneuroim.2009.02.008 · DOI
  19. Joice S. L., 2009, Brain Res., 1298, 13, 10.1016/j.brainres.2009.08.076 · DOI
  20. Lim J. C., 2008, J. Neurochem., 106, 1855, 10.1111/j.1471-4159.2008.05537.x · DOI · Paper page
  21. Luissint A. C., 2012, J. Cereb. Blood Flow Metab., 32, 860, 10.1038/jcbfm.2011.202 · DOI · Paper page
  22. Ohtsuki S., 2012, Drug Metab. Dispos., 40, 83, 10.1124/dmd.111.042259 · DOI · Paper page
  23. Kamiie J., 2008, Pharm. Res., 25, 1469, 10.1007/s11095-008-9532-4 · DOI · Paper page
  24. Ito S., 2006, Neurosci. Res., 56, 246, 10.1016/j.neures.2006.07.006 · DOI · Paper page
  25. Cornford E. M., 2005, NeuroRx, 2, 27, 10.1602/neurorx.2.1.27 · DOI
  26. Seetharaman S., 1998, J. Neurochem., 70, 1151, 10.1046/j.1471-4159.1998.70031151.x · DOI · Paper page
  27. Leong H. X., 2006, Nutr. Metab., 3, 37, 10.1186/1743-7075-3-37 · DOI
  28. Liu X. M., 2004, FASEB J., 18, 768, 10.1096/fj.03-0886fje · DOI · Paper page
  29. Boado R. J., 2003, J. Neurochem., 85, 1037, 10.1046/j.1471-4159.2003.01757.x · DOI
  30. Piehler A. P., 2012, Front. Psychiatry, 3, 17, 10.3389/fpsyt.2012.00017 · DOI · Paper page
  31. Yoshida I., 2004, Biochem. Biophys. Res. Commun., 323, 547, 10.1016/j.bbrc.2004.08.133 · DOI
  32. Kim W. S., 2006, NeuroReport, 17, 891, 10.1097/01.wnr.0000221833.41340.cd · DOI · Paper page
  33. Ito K., 2011, J. Pharm. Sci., 100, 3939, 10.1002/jps.22487 · DOI · Paper page
  34. Ciccimaro E., 2009, Anal. Chem., 81, 3304, 10.1021/ac900204f · DOI
  35. Domanski D., 2010, Anal. Chem., 82, 5610, 10.1021/ac1005553 · DOI · Paper page

Cited by

Metadata

Authors
Ohtsuki, S., Ikeda, C., Uchida, Y., Sakamoto, Y., Miller, F., Glacial, F., Decleves, X., Scherrmann, J.-M., Couraud, P.-O., Kubo, Y., Tachikawa, M., & Terasaki, T.
Venue
Molecular Pharmaceutics
Published
2012-12-11
Volume
10
Issue
1
Pages
289-296
ISSN
  • 1543-8384 (ISSN-L)
  • 1543-8392
OpenAlex
W2059636317
Cited by
230
References
6
FWCI
8.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.